Zoetis (ZTS) Non Operating Income (2012 - 2026)
Zoetis' (ZTS) quarterly Non Operating Income came in at $20.0 million in Q1 2026, up 33.33% year-on-year from $15.0 million in Q1 2025, and up 122.22% on a QoQ basis from $9.0 million in Q4 2025.
Zoetis (ZTS) Non Operating Income (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Non Operating Income data on file, last reported at $20.0 million in Q1 2026.
- On a quarterly basis, Non Operating Income rose 33.33% year-over-year to $20.0 million in Q1 2026; TTM through Mar 2026 was $38.0 million, a 46.15% increase from a year earlier, with the FY2025 full-year figure at $36.0 million, up 89.47% from the prior year.
- Non Operating Income for Q1 2026 stood at $20.0 million, up from $9.0 million in the prior quarter.
- Over the last five years, Non Operating Income for ZTS reached as high as $104.0 million in Q2 2023 and fell as low as -$34.0 million in Q4 2022.
- Historically, Non Operating Income has averaged $11.2 million across 5 years, with a median of $8.0 million in 2023.
- On a YoY basis, Non Operating Income climbed as much as 5300.0% in 2023 and fell as far as 300.0% in 2023.
- Year by year, Non Operating Income stood at -$34.0 million in 2022, then soared by 123.53% to $8.0 million in 2023, then surged by 150.0% to $20.0 million in 2024, then sank by 55.0% to $9.0 million in 2025, then surged by 122.22% to $20.0 million in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were $20.0 million in Q1 2026, $9.0 million in Q4 2025, and $13.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -7.50 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -13.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.00 Mn |
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | 13.00 Mn |
| Jun 30, 2025 | -4.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 20.00 Mn |
| Sep 30, 2024 | 16.00 Mn |
| Jun 30, 2024 | -25.00 Mn |
| Mar 31, 2024 | 8.00 Mn |
| Dec 31, 2023 | 8.00 Mn |
| Sep 30, 2023 | -6.00 Mn |
| Jun 30, 2023 | 104.00 Mn |
| Mar 31, 2023 | 53.00 Mn |
| Dec 31, 2022 | -34.00 Mn |
| Sep 30, 2022 | 3.00 Mn |
| Jun 30, 2022 | -2.00 Mn |
| Mar 31, 2022 | -7.00 Mn |
| Dec 31, 2021 | -32.00 Mn |
| Sep 30, 2021 | -4.00 Mn |
| Jun 30, 2021 | -10.00 Mn |